Corcept Therapeutics Incorporated (CORT)

In our clinical practice, we are seeing notable traction with LIFYORLI in platinum-resistant ovarian cancer, backed by the fact that over 1,000 prescribing physicians are now utilizing it and insurance coverage policies have expanded to cover more than 70% of relevant insured lives. When evaluating protocol execution, clinicians are paying close attention to upcoming milestones, including the FDA's December 17, 2026 action date for the resubmitted relacorilant application in Cushing's syndrome, as well as ongoing pipeline readouts spanning oncology, MASH, and ALS.

On our desk, the consensus is that CORT's 167% year-to-date surge reflects incredible commercial execution, but the valuation is extremely demanding. With LIFYORLI hitting $47.6 million in its first full quarter and management lifting 2026 revenue guidance to between $1.1 billion and $1.2 billion, the growth story is undeniable. However, trading near a $12.7 billion market cap while only passing 1 of 6 Simply Wall St valuation checks, the market has already priced in a pristine trajectory, leaving us sidelined with a Hold rating.

Watching the macro-risk factors from a quantitative standpoint, CORT's recent 5-year return of roughly 4.4x sets a very high bar for incremental buyers. While Q2 earnings easily beat expectations at 36 cents per share versus a consensus loss of 4 cents, high SGandA costs, generic risks, and the speculative nature of early-stage pipeline assets outside of Korlym and LIFYORLI introduce asymmetric downside risk if commercial growth stumbles or regulatory delays hit the December relacorilant decision.